Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Understanding molecular mechanisms of malignant tumors is crucial for developing targeted therapies.
• Stathmin is frequently over-expressed in various human cancers, promoting tumor development.
• Down-regulating stathmin can inhibit cancer cell proliferation, motility, metastasis, and induce apoptosis.

Approach:

• This review synthesizes recent 5-year research on stathmin's role in tumorigenesis.
• It examines the molecular mechanisms underlying stathmin's function in cancer.
• The review covers the development of anti-stathmin therapeutic strategies.

Key Points:

• Stathmin over-expression correlates with tumor progression.
• Targeting stathmin, via inhibitors like antibodies or small molecules, is a potential therapeutic avenue.
• Stathmin antagonists can reduce cancer cell proliferation and metastasis while promoting apoptosis.

Conclusions:

• Further investigation into stathmin's function in tumorigenesis is warranted.
• Developing rationally designed therapeutics targeting stathmin could lead to effective treatments for human malignant tumors.
• Stathmin antagonists represent a novel strategy for molecular targeted cancer therapy.